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Objective: Abdominal aortic aneurysms (AAAs) share common risk factors with atherosclerosis, except for diabetes which
appears protective. The reason for this is unknown. Although increased circulating concentrations of advanced glycation
endproducts (AGEs) such as carboxymethyllysine (CML) are associated with occlusive vascular disease, it is possible that
their effects on the aortic wall explain the paradoxically low incidence of AAAs in diabetes.
Methods:We studied 234 community-dwelling men aged 65 to 79 years. The cases comprised all identifiable diabetic men
with AAA (aortic diameter>30mmon ultrasound; n 27) and randomly-selected non-diabetic men with AAA (n 67).
Controls were age-matched randomly-selected diabetic men (n  69) and age-matched randomly-selected non-diabetic
men (n  71) without AAA (aortic diameter 18 to 22 mm). Serum CML concentrations were measured by validated
indirect enzyme-linked immunosorbent assay (ELISA).
Results: Serum CML concentrations were significantly lower in men with AAAs than those without (6627  1544 vs
7309 1490 nmol/mol lysine; P .001). Variables positively associated with AAAwere height, diastolic blood pressure,
smoking, a history of coronary heart disease, and serum creatinine (P < .040), while serum CML (odds ratio [95%
confidence interval] per 1000 nmol/mol lysine; 0.80 [0.64-0.98]) and a history of diabetes were inversely associated (P<
.040). After adjusting, the interaction between diabetes status and serum CML was negatively associated with AAA (P
.016).
Conclusion: These cross-sectional data show that circulating concentrations of CML are reduced in diabetic men with
AAAs. This is in contrast to studies of the relationship between AGEs and occlusive manifestations of cardiovascular
disease and could explain the inverse association between diabetes and AAA. (J Vasc Surg 2009;50:626-31.)
Clinical Relevance: In contrast to most manifestations of cardiovascular disease, diabetes protects against abdominal
aortic aneurysms (AAAs). The basis for this is unknown. We assessed a circulating marker of the glycation pathway,
carboxymethyllysine (CML), and found levels to be significantly lower in diabetic men with AAAs compared with those
without AAAs, supporting the hypothesis that advanced glycation may play a role in the negative association between
diabetes and AAA. This may be of relevance to the pathogenesis of AAAs, and in the context of diabetes, may be important
in the assessment of drugs that inhibit AGE formation.Abdominal aortic aneurysms (AAAs) are often attrib-
uted to atherosclerosis but the relationship may be one of
association rather than causation.1,2 Patients with these two
diseases share many common risk factors, notably male
gender, increasing age, and smoking.3 One risk factor for
atherosclerosis that AAAs do not share is diabetes.4 In a
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626large screening study of 100,000 subjects, those with
diabetes were half as likely to have an AAA as people
without diabetes.3 This inverse association has been con-
firmed in other population-based studies.5,6 In a study of
older diabetic men, the prevalence of AAAs was 2.3%
compared with 7% in all men over 65 years of age.7,8
Diabetes is also associated with reduced rates of expansion
of AAAs.9,10 In non-diabetic men, the fasting serum glu-
cose concentration has an inverse relationship with aortic
diameter throughout its range.6
Circulating concentrations of advanced glycation end-
products (AGEs) reflect dietary intake of preformed AGEs
and the effects of metabolic stress including hyperglycae-
mia. A variety of epidemiological and experimental data
show a strong association between AGEs and the develop-
ment of atherosclerosis.11 Circulating AGEs interact with
specific receptors to promote inflammation and endothelial
dysfunction, and bind and crosslink extracellular matrix to
reduce vascular compliance.12 Although AGEs are thought
to play a pivotal role in the development of diabetic vascular
complications,13 it is also possible that their effects on
proteins, in particular cross-linking within the vessel wall,
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AAAs.14
Carboxymethyllysine (CML) is the dominant and best
characterized circulating AGE.12,15 Circulating concentra-
tions of CML are increased in diabetes and vascular dis-
ease16 and are associated with increased arterial stiffness.17
Based on these observations and the epidemiological evi-
dence of a protective effect of diabetes, we postulated that
serum CML concentrations would be paradoxically re-
duced in diabetic patients with AAAs. The aim of the
present study was, therefore, to compare circulating levels
CML in community-dwelling diabetic and non-diabetic
older men with and without AAAs.
PATIENTS AND METHODS
Subject recruitment, assessment and selection.
Details of the Western Australian trial of AAA screening are
described elsewhere.18,19 Briefly, between January 1996
and December 1998 men aged 65 to 79 years were identi-
fied and recruited from the electoral roll and invited to
attend for screening. Each man completed a questionnaire
detailing aspects of history and lifestyle relevant to cardio-
vascular disease (CVD) including smoking status, exercise,
and a history of, or treatment for, coronary heart disease
(CHD), hypertension, dyslipidaemia, or diabetes. Inter-
mittent claudication was assessed using the Edinburgh
Claudication Questionnaire (ECQ).20
A nursemeasured height, weight, hip and waist circum-
ference, and blood pressure. The maximum diameter of the
infra-renal aorta was measured using a Toshiba Capasee
ultrasound machine with a 3·75 M Hz probe (Toshiba
Australia, North Ryde, NSW, Australia). After baseline
screening, all men found to have large AAAs (50 mm)
were referred back to their General Practitioner for further
management. Men with aortic diameters in the range 30 to
50mmparticipated in a separate study of expansion of small
AAAs.21 Between November 2001 and August 2004, all
surviving men from the original cohort were invited to
participate in a follow-up study, which included another
questionnaire and fasting venous blood sampling for mea-
surement of serum glucose, lipids, creatinine, homocys-
teine, and C-reactive protein. Informed consent was ob-
tained at both the baseline and follow-up visits, and
relevant Institutional Ethics Committees approved the
study protocol.
Cases of AAA were defined as men with an aortic
diameter of 30mm ormore and controls as men with aortic
diameters in a previously defined reference range (18 to 22
mm).22 Men were considered to have diabetes on the basis
of a positive response to questions about having diabetes,
age at diagnosis, and about type of treatment. In the
present study, cases comprised all identifiable diabetic men
with AAA (n  27) and randomly-selected non-diabetic
men with AAA (n  67), and the controls were age-
matched randomly-selected diabetic men (n  69) and
age-matched randomly-selected non-diabetic men (n 
71) without AAA.Biochemical assays. Serum cholesterol, high-density
lipoprotein (HDL), low-density lipoprotein (LDL), trig-
lycerides, glucose, creatinine, C-reactive protein (CRP),
and homocysteine were all measured on the day of blood
sampling using standard automated assays. CML concen-
trations were measured by an in-house indirect enzyme-
linked immunosorbent assay (ELISA) using archived eth-
ylenediaminetetraacetic acid (EDTA) plasma samples that
had been stored at 80°C until testing. CML in plasma is
considered to be stable when measured in protein bound
fractions. We have previously tested this ELISA in pilot
studies in non-diabetic and diabetic subjects and results
were consistent with those previously obtained by other
groups (unpublished data). A seven point standard curve
was constructed using AGE-modified human serum albu-
min (AGE-HSA) with a known CML content as measured
by a previously validated ELISA.23 AGE-HSA was gener-
ated by incubating fatty acid free, cold ethanol precipitated
fraction V of human serum albumin (50 mg/ml; Sigma
Chemical Co, St Louis,MO) in the presence and absence of
0.5 M D-glucose in 0.4 M phosphate buffer, pH 7.4 at
37°C for 12 weeks under aerobic conditions following filter
sterilization through 0.2 m filters.24 The preparations
were then dialysed (14 kDa exclusion) against four changes
of tissue culture grade phosphate buffered saline prepared
in milliQ water at 4°C overnight. Endotoxin was then
removed from dialysed preparations by Detoxigel columns
(Pierce, Rockford, IL) according to the manufacturer’s
instructions, followed by filter sterilization through 0.2 m
filters and stored desiccated at 80°C. Endotoxin levels in
AGE-albumin preparations were assessed by limulus amoe-
bocyte lysate (LAL) validation using the Kinetic Chromo-
genic method TM125 (AMS Laboratories, Rockford,
Australia). The LAL assay lower detection limit was 2.5
endotoxin units (EU)/ml in a stock concentration of 50
mg/mL.
Aliquots of 100 L of diluted samples or standards,
diluted in 50 mM carbonate buffer (pH 9.6) were added to
a microtitre plate (Nunc-Immuno MaxiSorp, Nunc, Kam-
strup, Roskilde, Denmark) and incubated overnight at 4°C.
All of the following procedures were performed at room
temperature. After washing three times with phosphate-
buffered saline (PBS, pH 7.4) containing 0.1% Tween-20
(Sigma, St Louis, MO), wells were blocked for 1 h with
phosphate buffered saline (PBS), pH 7.4 containing 1%
BSA (Sigma) and then 100 L of a rabbit polyclonal
anti-CML antibody (1.25 g/mL) was added. The anti-
body was generated in New Zealand white rabbits by
multiple immunizations with AGE-HSA. After 2 h wells
were washed three times and 100 l of 0.2 g/ml goat-
anti-rabbit IgG biotinylated antibody (Dako Corporation,
Carpinteria, CA) was added to each well. After 1 h of
shaking, wells were washed and 100 L of streptavidin
horseradish peroxidase (Dako Corporation), diluted 1/5000
was added. After 30 min, the wells were developed with
100 L of TMB substrate (Sigma Chemical Co) and the
reaction was terminated after 15 min with 1.8M H2SO4.
The absorbance was quantitated using a microtitre plate
ary he
Low-
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The limit of detection of the assay was 0.2 nmol/mol
lysine. The intra- and inter-assay coefficients of variation
were 5.4% and 7.9% respectively. The linearity of dilution of
the assay was r2 0.93. Results are expressed in nmol/mol
lysine.
Statistical methods. The data were analysed using
SPSS for Windows (version 15.0; SPSS Inc., Chicago, IL).
Estimated glomerular filtration rate (eGFR) was calculated
from the four variable Modification of Diet in Renal Dis-
ease Study Equation.25 Since serum triglycerides, serum
creatinine, homocysteine, and C-reactive protein were not
normally distributed, they were natural log (ln) trans-
formed before analysis. Data are presented as proportions,
mean ( standard deviation), geometric mean (SD range)
or, in the case of variables which did not conform to a
normal distribution, median (inter-quartile range [IQR]).
Two-sample comparisons of proportions were by Fisher’s
exact test, for normally distributed variables by Student’s
t test, and for non-normally distributed variables by the
Mann-Whitney U-test. Multivariate logistic regression
analysis (forward conditional, variable entry and removal
with P  .05 and P  .10, respectively) was performed to
identify independent associates of an aortic diameter 30
Table I. Characteristics of sub-groups of men with and w
Con
(n 
Aortic diameter (mm) 21.1
Age (years) 71.9
BMI (kg/m2) 27.0
Height (cm) 171.2
Waist (cm) 99.2
Waist:hip ratio 0.96
Systolic blood pressure (mmHg) 153
Diastolic blood pressure (mmHg) 88
Treatment for hypertension (%) 42
Treatment for dyslipidemia (%) 24
Diet for dyslipidemia (%) 8
Ever smoked (%) 65
Current smoker (%) 3
Non-vigorous exercise (%) 68
Past history of diabetes (%) 49
Aspirin treatment (%) 38
Previous CHD (%) 27
Intermittent claudication (%) 20
Serum CML (nmol/mol lysine) 7309
Serum total cholesterol (mmol/L) 4.7
Serum HDL-cholesterol (mmol/L) 1.34
Serum LDL-cholesterol (mmol/L) 2.7
Serum triglycerides (mmol/L) 1.3 (0.
Serum glucose (mmol/L) 5.8 (5.
Plasma homocysteine (mmol/L) 13.2 (10
Serum CRP (mg/L) 1.8 (0.
Serum creatinine (mol/L) 92 (74
eGFR (ml/min/1.73 m2) 76.8
Data are mean  SD, geometric mean (SD range), or median (interquartile
AAA, Abdominal aortic aneurysm; BMI, Body mass index; CHD, Coron
Estimated glomerular filtration rate; HDL, High-density lipoprotein; LDL,mm. All clinically plausible variables were considered forentry into the model. P  .05 was considered significant
throughout.
RESULTS
The anthropometric, clinical, and laboratory character-
istics of cases and controls are summarized in Table I.
Those with AAAs were significantly taller and more cen-
trally obese than those without AAAs. They were more
likely to be current or ex-smokers, to have an adverse serum
lipid profile, and to have a history of CHD. They also had
higher mean serum homocysteine and CRP concentra-
tions. The mean eGFR was also lower in this group.
Serum CML concentrations were significantly lower in
men with AAAs compared with controls (see Table I).
When analyzed by diabetes status, this difference reached
statistical significance only in those with diabetes (see Table
II). Amongst diabetic men, there were no differences in the
duration of diabetes or type of treatment between those
with and without AAAs (data not shown). After adjusting
for eGFR amongst diabetic men, serumCML concentrations
remained significantly lower inmenwith AAAs (742 nmol/
mol lysine; P .001).
Variables independently associated with AAA in multi-
ple logistic regression analysis using the total sample are
t AAA from the Health in Men Study
AAA
(n  94) P-value
37.3  6.6 .001
72.4  4.3 .29
27.0  3.6 1.00
173.2  6.1 .021
101.0  10.0 .16
6 0.98  0.07 .049
157  23 .10
91  13 .06
51.1 .23
25.5 .88
14.9 .20
84.0 .002
12.8 .008
55.3 .053
28.7 .002
47.9 .18
46.8 .003
20.2 1.00
90 6627  1544 .001
4.5  0.8 .042
7 1.23  0.27 .013
2.6  0.8 .30
) 1.3 (0.8-2.0) .81
) 5.5 (5.0-6.3) .009
.3) 14.7 (10.2-21.2) .013
) 2.3 (0.8-6.3) .059
) 102 (76-138) .005
.6 69.6  21.3 .007
[IQR]).
art disease; CML, Carboxymethyllysine; CRP, C-reactive protein; eGFR,
density lipoprotein.ithou
trol
140)
 2.2
 3.8
 3.4
 6.7
 9.5
 0.0
 19
 11
.2
.4
.9
.0
.1
.6
.3
.5
.9
.7
 14
 1.0
 0.3
 0.9
8-2.1
2-7.4
.1-17
7-4.7
-115
 18
rangeshown in Table III. After adjusting for this most parsimo-
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serum CML was negatively associated with AAA (P 
.016). Whenmen with diabetes were considered separately,
height and waist:hip ratio were positive independent asso-
ciates of AAA whilst CML level was negatively associated
(see Table IV).
DISCUSSION
The present cross-sectional study has shown, for the
first time, that circulating concentrations of CML, a marker
of advanced glycation, are reduced in older diabetic men
with AAAs. This is in contrast to studies of the relationship
between AGEs and occlusive manifestations of cardiovas-
cular disease,11 including diabetic angiopathy.12,13 The
present data suggest that accelerated advanced glycation
may explain the results of epidemiological studies showing
a clear inverse association between diabetes and AAA.3,5-7
This protective mechanism does not appear to be present in
Table II. Mean  SD serum CML in nmol/mol lysine
by AAA and diabetes status
No AAA AAA P-value
No diabetes 6917  1361
(n  71)
6749  1615
(n  67)
.51
Diabetes 7712  1518
(n  69)
6326  1332
(n  27)
.001
P-value .001 .23
AAA, Abdominal aortic aneurysm; CML, Carboxymethyllysine.
Table III. Variables independently associated with AAA
in multiple linear regression analysis of the total sample
Odds ratio (95%
confidence interval) P-value
Height (per 1cm) 1.06 (1.01-1.12) .012
Diastolic blood pressure (per 10
mm Hg) 1.36 (1.03-1.80) .029
Current smoker 3.96 (1.09-14.41) .037
History of CHD 3.49 (1.81-6.73) .001
Ln (serum creatinine [mol/L]) 5.22 (1.50-18.17) .009
Serum CML (per 1000 nmol/
mol lysine) 0.80 (0.64-0.98) .034
History of diabetes 0.51 (0.27-0.97) .040
AAA, Abdominal aortic aneurysm; CHD, Coronary heart disease; CML,
Carboxymethyllysine.
Table IV. Multiple logistic regression analysis of
variables associated with AAA in men with diabetes
Odds ratio (95%
confidence interval) P-value
Height (per 1 cm) 1.12 (1.02-1.22) .016
Waist:hip ratio (10 cm per 1 cm) 2.22 (1.04-4.73) .039
Serum CML (per 1000 nmol/
mol lysine) 0.49 (0.32-0.76) .001
AAA, Abdominal aortic aneurysm; CML, Carboxymethyllysine.people without diabetes.The walls of AAAs show evidence of chronic inflamma-
tion, increased proteolytic activity, accelerated collagen
turnover, and elastin depletion. These processes result in
progressive damage to the aortic matrix, with gradual aortic
expansion and the potential for rupture.26,27 In contrast,
diabetes is characterized by increased matrix volume, re-
sulting in changes such as basement membrane thickening
and mesangial expansion.28 This appears to be due to a
combination of increased synthesis and reduced degrada-
tion of matrix.29,30 Diabetes results in an increase in aortic
intima-media thickness and, because of this, a reduction in
aortic wall stress,31 whereas aneurysmal disease is associated
with increased aortic wall stress and reduced wall thick-
ness.32 These anatomical and physiological differences are
consistent with the negative association between diabetes
and AAA being due to differences in vascular matrix.14
Increased advanced glycation is another pathological
consequence of diabetes and is a plausible explanation for
the protection against AAA formation. AGEs form non-
enzymatic cross-links in extracellular matrix that involve
both collagen and elastin.33,34 In vitro studies indicate that
AGE-mediated cross-links are resistant to proteolysis.10
Glycation impairs MMP activation and stimulates collagen
synthesis via protein kinase C and transforming growth
factor- up-regulation.35 The resultant environment is one
with reduced matrix proteolysis and increased synthesis
within the arterial wall, which is the opposite of changes
seen in the walls of aneurysmal aortas.
Another possible explanation for the negative associa-
tion between diameter and diabetes involves homocysteine.
Elevated plasma homocysteine concentrations have been
implicated in the pathogenesis of AAAs.36 Although homo-
cysteine levels eventually rise in diabetic individuals as
eGFR declines, levels in pre-diabetic states and early in the
course of type 2 diabetes may be lower than normal due to
hyperfiltration.37 In the present study, mean plasma homo-
cysteine concentrations were lower in men with AAAs than
in those without, however there was no evidence of inter-
action with diabetic status or serum CML concentration.
Due to the long natural history of both AAA formation and
impaired glycemic control, it remains unclear whether in-
creasing advanced glycation associated with the develop-
ment of diabetes stops progression of an existing AAA.
Diabetes is associated with slower progression of AAAs,9,21
although serum CML concentrations did not predict the
rate of expansion of screen-detected AAAs in a recent
study.10
Other independent predictors of AAA in our patients
including smoking and past CHD were similar to those
identified in previous studies.1,3 Indeed, the fact that there
were lower serum CML concentrations but a higher prev-
alence of CHD in our patients with AAA suggest that AGEs
have a greater influence on aneurysmal than on occlusive
vascular disease. Although increased serum CML concen-
trations are likely to be a cause rather than a consequence of
renal impairment,38 eGFR was included in the multivariate
model in which CML remained a significant inverse predic-
tor of AAAs.
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and relatively small groups of subjects mean that our find-
ings need to be examined in longitudinal studies in which
serumCML and other markers of the glycation pathway are
examined in individuals with and without diabetes who
have serial measurements of aortic diameter. Such studies
could also assess additional influences on circulating con-
centrations of AGEs not addressed in the present study
including dietary sources and the effects of vitamins such as
benfotiamine, pyridoxamine, and ascorbic acid. Ironically,
the interest in pharmacological control of advanced glyca-
tion as prevention and treatment for occlusive vascular
disease may provide an additional source of relevant data.
Drugs that inhibit AGE formation such as aminoguanidine
and pyridoxamine, and AGE cross-link breakers such as
alagebrium,39,40 could increase the risk of AAAs. It would
be hoped that intervention trials assessing these therapies
would include aortic diameter as a safety endpoint.
Special thanks to all men and staff who participated in
the Western Australian Abdominal Aortic Aneurysm Pro-
gram and the Health In Men Study.
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